Neuraminidase Inhibitors Drug Market Share

  • Report ID: 2563
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Neuraminidase Inhibitors Drug Market Share

North America industry is poised to dominate majority revenue share by 2037, as the region is highly developed since the technological advancement is rapid along with good infrastructure. This boosts the market growth as demand is estimated to rise. The market in the Asia pacific region is anticipated to grow as a result of rising cases of influenza in the region and the development is under process. Further, people are becoming aware of the disease and its treatment.

Research Nester
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2563
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of neuraminidase inhibitors drug is estimated at USD 110.95 billion.

Neuraminidase Inhibitors Drug Market size was valued at USD 104.8 billion in 2024 and is set to exceed USD 249.5 billion by 2037, expanding at over 6.9% CAGR during the forecast period i.e., between 2025-2037.

North America industry is poised to dominate majority revenue share by 2037, as the region is highly developed since the technological advancement is rapid along with good infrastructure.

The major players in the market are F. Hoffmann La Roche, GlaxoSmithKline plc, Gilead Sciences, Daiichi Sankyo, BioCryst Ltd., and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample